Home / Investors
Investor information
The company’s announcements, its share facts and the contact it publishes for investor enquiries.
Share facts
- SymbolRSPI — quoted on the OTC Pink Market
- CUSIP761227305
- IncorporatedDelaware
- Transfer agentAST Financial LLC (formerly American Stock Transfer and Trust Company), 6201 15th Ave, Brooklyn, NY 11219 · (800) 937-5449
- DividendNone paid historically; none anticipated
- DRIPNone
- Direct purchaseNo direct purchase plan — shares through a broker
These are the answers the company publishes in its own FAQ.
News
Announcements
As published on the company’s news page, most recent first.
Letter to stockholders and other interested parties
NIH/NINDS grant award and amended and restated patent license agreement with the University of Wisconsin–Milwaukee Research Foundation
Commencement of a Rule 506(c) private placement
SEC order making findings and revoking registration of securities, and future plans
CFO and CEO issue letter to stockholders and other interested parties
Department of Defense award to fund a Phase 2 study of CX1739 to improve bladder function in spinal cord injury
Publication of preclinical results showing CX1739 improves bladder function after spinal cord injury
Preclinical pain relief reported for the non-opioid lead GABAkine
Appointment of Dr. Dariusz Naziek to the Board of Directors
Case report: KRM-II-81 suppressed epileptiform activity in human brain tissue
Videos
Investor briefings
Published by the company. Click to play — nothing loads from YouTube until you do.
Investor contact
Jeff Margolis
Senior Vice President, Chief Financial Officer, Secretary, Treasurer and member of the Board of Directors.
RespireRx invites any and all inquiries pertaining to corporate information and investment opportunities.
- AddressRespireRx Pharmaceuticals Inc.
126 Valley Road, Suite C
Glen Rock, New Jersey 07452 - Phone(917) 834-7206
- Emailjmargolis@respirerx.com